Immunogenomics Market Report 2026

The immunogenomics market size has grown rapidly in recent years. It will grow from $6.09 billion in 2025 to $7.07 billion in 2026 at a compound annual growth rate (CAGR) of 16.1%. The growth in the historic period can be attributed to advancements in genomic sequencing technologies, growing understanding of immune-related genetic variations, expansion of oncology and infectious disease research, increased research funding, availability of high-throughput genomic tools.

The immunogenomics market size is expected to see rapid growth in the next few years. It will grow to $12.73 billion in 2030 at a compound annual growth rate (CAGR) of 15.8%. The growth in the forecast period can be attributed to increasing demand for precision medicine solutions, rising development of personalized vaccines and immunotherapies, expansion of translational immunogenomics research, growing integration of multi-omics data, increased adoption of cloud-based genomic analytics. Major trends in the forecast period include increasing adoption of next-generation sequencing in immune profiling, rising use of bioinformatics tools for immune data analysis, growing focus on personalized immunotherapies, expansion of genomic databases for immune research, enhanced integration of ai in immunogenomic studies.

The rising prevalence of infectious diseases is expected to propel the growth of the immunogenomics market going forward. Infectious diseases are illnesses caused by pathogens such as bacteria, viruses, fungi, or parasites that spread between individuals. Their increasing prevalence is driven by global travel, which accelerates pathogen transmission. Immunogenomics improves infectious disease management by analyzing immune responses and genetic susceptibility, enabling better diagnostics, vaccine development, and personalized therapies. For instance, in February 2024, according to the UK Health Security Agency, tuberculosis cases in England increased by 10.7% in 2023. Therefore, the rising prevalence of infectious diseases is contributing to the growth of the immunogenomics market.

Leading companies operating in the immunogenomics market are focusing on developing advanced solutions, such as vaccine target prediction systems, that enable automated end-to-end vaccine design and optimize vaccine constructs by ensuring optimal antigen sequencing. Vaccine target prediction systems are computational platforms that use bioinformatics algorithms alongside genomic and immunomic data to identify potential antigen molecules from pathogens or cancer cells and analyze structural characteristics to prioritize and select optimal vaccine candidates with high potential to elicit protective immune responses. For instance, in September 2024, Evaxion Biotech A/S, a Denmark-based biotechnology company specializing in artificial intelligence-driven immunotherapy and vaccine development, launched the clinically validated AI-Immunology platform, an upgraded EDEN artificial intelligence prediction model that includes a novel toxin antigen predictor to improve the accuracy and reliability of bacterial toxin antigen identification for next-generation bacterial vaccine development. Additionally, the platform simulates the immune system to support the creation of personalized and next-generation immunotherapies and has shown strong correlations between AI-generated predictions and clinical outcomes.

In January 2025, Adaptive Biotechnologies Corp., a US-based biotechnology company, partnered with NeoGenomics Laboratories Inc. to expand advanced immunogenomic testing services. This partnership aims to increase access to personalized minimal residual disease (MRD) monitoring for blood cancer patients by integrating advanced sequencing and diagnostic technologies to support tailored treatment and improved patient care. NeoGenomics Laboratories Inc. is a US-based testing company specializing in immunogenomics services.

Major companies operating in the immunogenomics market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Illumina Inc., BGI Group, GenScript Biotech Corporation, CareDx Inc., Oxford Nanopore Technologies plc, Genewiz LLC, Adaptive Biotechnologies Corporation, GenomOncology LLC, Personalis Inc., Variantyx Inc., CD Genomics Inc., Sengenics Corporation, GeneCentric Therapeutics Inc., Immunogenomics Inc., ImmuQuad Biotechnologies Inc., Neomics Pharmaceuticals LLC, Yemaachi Biotech Ltd., BioAnalytica Biotechnology Systems Inc.

North America was the largest region in the immunogenomics market in 2025. The regions covered in the immunogenomics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the immunogenomics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the immunogenomics market by increasing costs of imported sequencing instruments, reagents, consumables, bioinformatics hardware, and specialized laboratory equipment. Research institutes and biotechnology companies in North America and Europe are most affected due to reliance on imported genomic technologies, while Asia-Pacific faces higher costs in scaling immunogenomic research programs. These tariffs are raising research expenditures and slowing procurement cycles. However, they are also encouraging domestic production of genomic consumables, regional technology partnerships, and development of cost-efficient immunogenomic platforms.

The immunogenomics market research report is one of a series of new reports that provides immunogenomics market statistics, including immunogenomics industry global market size, regional shares, competitors with a immunogenomics market share, detailed immunogenomics market segments, market trends and opportunities, and any further data you may need to thrive in the immunogenomics industry. This immunogenomics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Immunogenomics is a specialized area of genomics that examines how an individual’s genetic composition influences immune system function. It focuses on identifying genetic variations that affect immune responses, vulnerability to infectious and autoimmune diseases, and the effectiveness of immunotherapies and vaccines.

The primary product types of immunogenomics are instruments, consumables, software, and services. Instruments in immunogenomics are laboratory devices used to analyze genetic material and study immune system function, including sequencers, microarray scanners, and cell sorters. The technologies employed include next-generation sequencing, microarray, polymerase chain reaction, and others. Applications cover oncology, infectious diseases, autoimmune disorders, transplantation, and others, serving end-users such as hospitals and clinics, research institutes, pharmaceutical and biotechnology companies, and others.

The immunogenomics market also consists of revenues earned by entities by providing services such as immune profiling, bioinformatics analysis, biomarker discovery, and immunotherapy support. The market value includes the value of related goods sold by the service provider or included within the service offering. The immunogenomics market also includes sales of sequencing kits, reagents, microarrays, and bioinformatics tools. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.